Quarterly report · Q2
3034.TEDINET S100SA13
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥82.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥101.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥91.0bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥57.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥53.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥45.9bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.58 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.11 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.92 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥231m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥231m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.6bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥167m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥658m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥231m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.9bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥123m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥645m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥82.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥82.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥181m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥5.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 7582800 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2011 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 3842600 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1019 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1777915 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0471 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1641000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0435 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1590500 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0421 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 1370200 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0363 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1304000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0345 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1104000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0292 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 1094900 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0290 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 784000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0207 | |
| Number of shares held | CurrentQuarterInstant | 22091915 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5859 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1200200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 37672500 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 376725 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 30085 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 38902785 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 376725 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1200200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 1200200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0308 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 1200200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 1200200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0308 | |
| Cash and deposits | Prior1YearInstant | 18770000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 17428000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 16951000000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 16505000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 4990000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 5429000000 | JPY |
| Work in process | Prior1YearInstant | 90000000 | JPY |
| Work in process | CurrentQuarterInstant | 143000000 | JPY |
| Supplies | Prior1YearInstant | 205000000 | JPY |
| Supplies | CurrentQuarterInstant | 188000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |